Medicare Part D Opioid Policies May Incorporate CDC Guidelines
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS notes some success in reducing the number of beneficiaries overusing opioids but proposes additional action for plans to manage access.
You may also be interested in...
Medicare Part D Plans To Control Opioid Access With ‘Lock In’ Program
Addiction prevention legislation empowers Medicare drug plans to restrict prescriber, pharmacy access to opioids for ‘at risk’ beneficiaries.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.